Chester County News and Community Website
LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) will engage investors next week as members of its management team participate in one-on-one meetings and fireside chats at two high-profile healthcare conferences.
Savara to Spotlight Lead Therapy in Fireside Chats at Major Healthcare Conferences Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) said it remains on track to resubmit its Biologics License Application for MOLBREEVI, a potential first-in-class treatment for autoimmune pulmonary alveolar proteinosis, in …
Savara Advances MOLBREEVI Toward Approval as Financing Boost Extends Cash Runway Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has entered into a $75 million royalty funding agreement with funds managed by RTW Investments, LP, contingent on U.S. Food and Drug Administration …
Savara Secures $75 Million Royalty Deal to Back Potential MOLBREEVI Launch Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) promoted Yasmine Wasfi, M.D., Ph.D., FCCP, to chief medical officer, succeeding Ray Pratt, M.D., FACP, who will become senior medical advisor. Wasfi, formerly …
Savara Elevates Dr. Yasmine Wasfi to CMO as Autoimmune PAP Program Advances Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) announced that its updated analysis of U.S. health claims data estimates approximately 5,500 patients are currently diagnosed with autoimmune pulmonary alveolar proteinosis (autoimmune …
Savara Increases Estimate of Autoimmune PAP Prevalence in U.S., Advances MOLBREEVI Toward FDA Resubmission Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) announced that its management team will participate in two upcoming healthcare conferences in September.
Savara to Present at Two Upcoming Healthcare Conferences Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) announced that the results of its Phase 3 IMPALA-2 clinical trial for molgramostim, an inhaled therapy for autoimmune pulmonary alveolar proteinosis (autoimmune PAP), …
Savara’s Phase 3 Trial Shows Promising Results for Rare Lung Disease Treatment Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) announced that three of its abstracts have been accepted for poster presentation at the European Respiratory Society (ERS) Congress 2025, taking place September …
Savara to Present Key Research on Rare Lung Disease at ERS Congress 2025 Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) reported second-quarter 2025 financial results and outlined key regulatory and business milestones, including plans to resubmit its Biologics License Application (BLA) for MOLBREEVI, …
Savara to Resubmit BLA for Rare Lung Disease Treatment as Losses Widen in Q2 Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) announced it has granted inducement awards to two new employees.
Savara Inc. Grants Inducement Awards to New Employees with Stock Options & RSUs Read More